Sequenom News

SAN DIEGO, May 29, 2012 /PRNewswire via COMTEX/ -- Sequenom, Inc. , a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Jefferies 2012 Global Healthcare Conference at the Grand Hyatt in New York, NY on June 4-7, 2012.

Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing.

SAN DIEGO, May 17, 2012 /PRNewswire/ -- Sequenom Inc., through its wholly owned subsidiary Sequenom Center for Molecular Medicine, LLC, entered into the recently announced provider network participation agreement with Coventry Health Care National Network, Inc.

Sequenom says the recently announced provider network participation agreement with Coventry Health Care has been terminated without cause by Coventry.

Sequenom Inc said insurer Coventry Health Care Inc will provide coverage for its prenatal test to detect certain chromosomal abnormalities including Down Syndrome.

I would now like to turn this conference over to Marcy Graham, Senior Director of Investor Relations.

SAN DIEGO, May 3, 2012 /PRNewswire/ -- Sequenom, Inc. , a life sciences company providing innovative genetic analysis solutions, today reported revenue of $14.9 million for the first quarter of 2012, an increase of 10% compared to revenue of $13.5 million for the first quarter of 2011.

The firm currently has an "outperform" rating on the stock. The analysts wrote, "While investors remain focused on the near termMaterniT21 ramp we see a number of positive catalysts on the horizon that could enhance long term value, including the signing of 2 major payor contracts and clarity on the FDA pathway.

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Trovagene, Inc. , a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of ... (more)